Close Menu

At In the Pipeline, Derek Lowe asks in which fields people would consider starting a small drug company. He writes that oncology would have been a good choice a decade ago and that going into cardiovascular disease and metabolic disorders doesn’t make much sense, unless you've been sitting on a golden egg. Alzheimer's disease, he says, is an under-served market, adding that "it's unserved for a lot of damned good reasons. The same goes for a number of other CNS indications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.